SEEBRI NEOHALER Rx
Generic Name and Formulations:
Glycopyrrolate 15.6mcg; per capsule; dry powder for oral inhalation for use with Neohaler device; contains lactose.
Indications for SEEBRI NEOHALER:
Long-term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.
For oral inhalation use only with Neohaler device; do not swallow caps. Administer at the same time of the day (AM + PM). Inhale contents of one capsule (15.6mcg) twice daily.
Do not initiate in patients during acutely deteriorating or potentially life-threatening COPD episodes. Not for treating acute symptoms. Do not exceed recommended dose. Discontinue immediately and treat if paradoxical bronchospasm or immediate hypersensitivity reactions occur; use alternative therapy. Severe milk protein hypersensitivity. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Severe renal impairment, including ESRD requiring dialysis. Pregnancy (Cat.C). Nursing mothers: not recommended.
Additive effects with concomitant other anticholinergic-containing drugs; avoid.
Upper respiratory tract infection, nasopharyngitis, urinary tract infection, sinusitis, oropharyngeal pain; paradoxical bronchospasm, hypersensitivity reactions.
Blister pack—60 (w. one Neohaler device)
Endocrinology Advisor Articles
- Soluble Klotho Levels Predictive of Kidney Failure in Type 2 Diabetes
- HbA1c Levels Predictive of Liraglutide Treatment Response in T2D
- Clinicians May Be Overtreating Older Patients With Diabetes
- Comorbid and Pharmacologic Factors Increase Risk for Gastrointestinal Disorders in Diabetes
- ADA Updates Guidelines for Cardiovascular Risk Management in Diabetes
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Hormonal Contraceptives May Adversely Affect Psychological Health in Adolescent Girls
- Obesity Can Negatively Effect Liver in Children as Young as 8
- Recommendations Developed on Gender Equity in Medicine
- Intensive Lifestyle Interventions Cut Long-Term Disability in Type 2 Diabetes